58.85 USD
↘ 0.18 (0.30%)AT CLOSE (11:59 AM EDT)
Travere Therapeutics, Inc. Common Stock
TVTXNASDAQ • USD
60.87
↗ 2.02 (3.44%)
POST MARKET (AS OF 06:36 PM EDT)
Post Market
AS OF 06:36 PM EDT
60.87
↗ 2.02 (3.44%)
Market: CLOSED
Travere Therapeutics, Inc. Common Stock (TVTX) trades at $58.85 per share. Technicals currently rate "Strong Buy" while our fundamental analysis reads "Neutral". This is driven by a robust Altman Z-Score, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. On the valuation front, TVTX trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Jun 26, 2026.
Open?$59.34
High?$59.81
Low?$57.69
Prev. Close?$59.03
Volume?4.9M
Avg. Volume?2.2M
VWAP?$58.81
Rel. Volume?2.18x
Bid / Ask
Bid?$57.80 × 100
Ask?$60.28 × 500
Spread?$2.48
Midpoint?$59.04
Valuation & Ratios
Market Cap?5.5B
Shares Out?93.0M
Float?90.4M
Float %?98.0%
P/E Ratio?N/A
P/B Ratio?55.43
EPS?-$0.23
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
Themes
Address
3611 VALLEY CENTRE DR
SAN DIEGO, CA 92130
Phone: 888-969-7879
SAN DIEGO, CA 92130
Phone: 888-969-7879
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?40
Z-Score?96
Momentum?57
Short Sent.?54
Piotroski F-Score?4/9Mixed
Altman Z-Score?4.59Safe
Confidence?64%Moderate
Short InterestHigh
Short % of Float?14.87%High
Short Interest?13.4M
Days to Cover?6.4
Free Float90.4M
Avg Daily Volume2.1M
Settlement Date2026-06-15
Financial Health
Current Ratio?3.13Strong
Quick Ratio?3.08Strong
Cash Ratio?0.62Adequate
Debt/Equity?3.16High
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score33/100
P/E?N/A▾
P/B?55.43HIGH▾
Peers100
S&P3
P/S?10.21HIGH▾
Peers100
S&P8
P/FCF?139.5PRICEY▾
Peers100
S&P3
EV/EBITDA?354.6HIGH▾
Peers100
S&P3
EV/Sales?10.64HIGH▾
Peers100
S&P9
Returns & Efficiency
ROE?-21.7%WEAK▾
S&P7
ROA?-3.9%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$39.2M
Enterprise Value?$5.7B
Fundamentals ratios updated end of day